CRA’s Life Sciences Practice was retained by a biotechnology company to perform a valuation of its gene editing patent portfolio, and to provide recommendations regarding potential licensing agreements with other companies. CRA developed a valuation model based on publicly available information relating to market opportunities, potential sales, and various risk factors for products in the field of human therapeutics. In addition to assisting the company in assessing the market potential for the use of the relevant patents in the fields of agriculture and research tools. CRA provided recommendations regarding the optimal royalty structure to include in potential future licensing agreements.
CRA consultants recognized among leading IP professionals in the 2025 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...


